Healthcare Costs — Better Living Through Chemistry
Kurt Brouwer November 30th, 2007
This article addresses a new diagnostic tool that promises to make early detection of health problems vastly simpler, less intrusive and more reliable. I am discussing it because it is an example of the almost daily improvements we see in healthcare. Take this advance along with dozens and hundreds of others and we begin to see glimmerings of a far different health landscape [emphasis added below]:
A new blood test promises to spot cancer and Alzheimer’s long before you get sick (Popular Science Magazine, November 2007, Kalee Thompson)
‘By the time a doctor diagnoses you with cancer or a neurodegenerative disease, you may have been living with it for years-a troubling fact, given that early detection is the most important factor in successful treatment. Now, Power3 Medical Products, a biotech firm in Houston, Texas, has developed simple, low-cost blood tests for breast cancer, Alzheimer’s and Parkinson’s that will allow physicians to spot disease the moment it shows up in a patient’s body-years earlier than today’s most advanced technologies can catch it. “With our tests, you don’t have to wait around for 6 or 10 years [to spot the problem],” says CEO Steven Rash…
…The new breast-cancer test is much less invasive than a mammogram or biopsy. A doctor samples a patient’s blood and sends it to Power3′s lab, where scientists search for 22 irregular proteins that Power3 has identified as early signs of breast cancer. Initially the test will debut in 40 clinics that treat women at high risk for breast cancer, Rash says. Women under 40 years of age with high-risk genetic or family factors should benefit the most, he adds, because their denser breast tissue makes mammography significantly less effective. Scientists have been working to develop proteomic tests for the past three years, but they were derailed by inconsistent test results. Early data indicate that Power3 has overcome this challenge. In a blind trial of 60 blood samples provided by Mercy Women’s Center in Oklahoma City, the test scored a 97 percent rate of identifying cancer in samples from diagnosed patients and a 93 percent rate of correctly identifying healthy women as cancer-free. A second 100-patient trial will be completed by the end of the year. In comparison, mammograms miss up to 30 percent of breast cancers, and 75 percent of the biopsies performed after an irregular mammogram prove benign…